


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (currently amended): A compound represented by the following formula (I):



wherein R^1 and R^2 each independently represents hydrogen, alkyl, alkenyl, alkynyl, aralkyl, amino, alkylamino, cyano, halogen, halogenoalkyl, halogenoalkenyl, halogenoalkynyl, carboxyl, alkoxycarbonyl, carbamoyl, *N*-alkylcarbamoyl, *N,N*-dialkylcarbamoyl, *N*-hydroxyalkylcarbamoyl, aryl which may have a substituent, a saturated or unsaturated 5- to 7-membered heterocyclic group which may have a substituent, a saturated or unsaturated bicyclic or tricyclic condensed heterocyclic group which may have a substituent, arylalkenyl which may have a substituent, saturated or unsaturated hetero ring alkenyl which may have a substituent, or saturated or unsaturated bicyclic or tricyclic condensed hetero ring alkenyl which may have a substituent, R^2 represents hydrogen, alkyl, amino, cyano, halogen, halogenoalkenyl, carboxyl, alkoxycarbonyl, carbamoyl, *N,N*-dialkylcarbamoyl, *N*-hydroxyalkylcarbamoyl, aryl which may have a substituent, a saturated or unsaturated 5- to 7-membered heterocyclic group which may have a substituent, or a saturated or unsaturated bicyclic or tricyclic condensed heterocyclic group which may have a substituent, wherein the substituent is one substituent or 2 or 3 substituents, which are the same or different, selected from the following Group (A):

Group (A):

halogen, hydroxyl, alkyl, alkoxy, halogenoalkyl, cyano, nitro, hydroxyalkyl, carboxyl, alkoxycarbonyl, carboxyalkoxy, alkoxycarbonylalkoxy, aralkyloxy, *N*-alkylaminoalkylcarbonyl, *N,N*-dialkylaminoalkylcarbonyl, carboxyalkyl, alkoxycarbonylalkoxy, morpholinocarbonylalkoxy, mercapto, alkylthio, aminosulfonyl, *N*-alkylaminosulfonyl, *N,N*-dialkylaminosulfonyl, sulfo, alkylsulfonyl, alkylsulfonylalkyl, tetrazolyl, trialkyltin, trialkylsilyl, aminosulfonylalkyl, *N*-alkylaminosulfonylalkyl, *N,N*-dialkylaminosulfonylalkyl, aralkyl, alkylsulfonylamino, *N*-alkylaminosulfonylamino, *N,N*-dialkylaminosulfonylamino, *N*-alkylaminoacylamino, *N,N*-dialkylaminoacylamino,

a group represented by the following formula (II):



wherein A^1 represents a single bond or linear, branched or cyclic alkylene having from 1 to 6 carbon atoms which may be substituted with halogen or hydroxyl; and Y^1 represents a saturated or unsaturated 5- to 7-membered heterocyclic group which may have a substituent,

wherein the substituent on Y^1 is one substituent or 2 or 3 substituents, which are the same or different, selected from the group consisting of halogen, alkyl, halogenoalkyl, carboxyl, alkoxycarbonyl, aminoalkyl, *N*-alkylamino, *N,N*-dialkylamino, *N*-alkylaminoalkyl, *N,N*-dialkylaminoalkyl, *N*-alkyl-*N*-alkoxycarbonylamino and *N*-alkyl-*N*-alkoxycarbonylaminoalkyl,

a group represented by the following formula (III)



wherein A^2 represents a single bond, linear, branched or cyclic alkylene having from 1 to 6 carbon atoms which may be substituted with halogen or hydroxyl, or linear, branched or cyclic-O-alkylene having from 1 to 6 carbon atoms which may be substituted with halogen or

hydroxyl, in which the alkylene binds to the carbonyl in the group; and Y^2 represents a saturated or unsaturated 5- to 7-membered heterocyclic group which may have a substituent,

wherein the substituent on Y^2 represents one substituent or 2 or 3 substituents, which are the same or different, selected from the group consisting of halogen, alkyl, halogenoalkyl, carboxyl, alkoxycarbonyl, aminoalkyl, *N*-alkylamino, *N,N*-dialkylamino, *N*-alkylaminoalkyl, *N,N*-dialkylaminoalkyl, *N*-alkyl-*N*-alkoxycarbonylamino and *N*-alkyl-*N*-alkoxycarbonylaminoalkyl,

a group represented by the following formula (IV)



wherein A^3 represents a single bond, linear, branched or cyclic alkylene having from 1 to 6 carbon atoms which may be substituted with halogen or hydroxyl, linear, branched or cyclic-O-alkylene having from 1 to 6 carbon atoms which may be substituted with halogen or hydroxyl, in which the alkylene binds to the nitrogen atom in the group, or linear, branched or cyclic-(C=O)-alkylene having from 1 to 6 carbon atoms which may be substituted with halogen or hydroxyl, in which the alkylene binds to the nitrogen atom in the group; and R^4 and R^5 each independently represents hydrogen, alkyl, hydroxyalkyl, halogenoalkyl, acyl, alkoxycarbonyl, alkylsulfonyl, *N*-alkylaminosulfonyl, *N,N*-dialkylaminosulfonyl, *N*-alkylaminoalkylcarbonyl, *N,N*-dialkylaminoalkylcarbonyl or alkylidiphenylsilyloxyalkyl, and

a group represented by the following formula (V)



wherein A^4 represents a single bond, linear, branched or cyclic alkylene having from 1 to 6 carbon atoms which may be substituted with halogen or hydroxyl, or linear, branched or

cyclic-O-alkylene having from 1 to 6 carbon atoms which may be substituted with halogen or hydroxyl, in which the alkylene binds to the carbonyl in the group; and

R⁶ and R⁷ each independently represents hydrogen, alkyl, hydroxyalkyl, halogenoalkyl, acyl, alkoxycarbonyl, alkylsulfonyl, *N*-alkylaminosulfonyl, *N,N*-dialkylaminosulfonyl, *N*-alkylaminoalkylcarbonyl, *N,N*-dialkylaminoalkylcarbonyl or alkylidiphenylsilyloxyalkyl;

R³ represents hydrogen, ~~alkyl which may have substituent, acyl or alkoxycarbonyl;~~

Ar represents phenylene ~~a divalent group derived from aromatic hydrocarbon, a saturated or unsaturated 5- to 7-membered hetero ring or a saturated or unsaturated bicyclic or tricyclic condensed hetero ring,~~ which may have one substituent or 2 or 3 substituents, which are the same or different, selected from the following Group (B):

Group (B):

halogen, hydroxyl group, alkyl, alkoxy, halogenoalkyl, cyano, amino, nitro, alkylamino, hydroxyalkyl, carboxyl, alkoxycarbonyl, carbamoyl, mercapto, alkylthio, aminosulfonyl, *N*-alkylaminosulfonyl, *N,N*-dialkylaminosulfonyl, sulfo, trialkyltin and trialkylsilyl;

X represents a single bond, ~~linear or branched alkylene having from 1 to 3 carbon atoms which may have a substituent, linear or branched alkenylene having from 1 to 3 carbon atoms which may have a substituent, linear or branched alkynylene having from 1 to 3 carbon atoms which may have a substituent or carbonyl; and~~

G represents halogen, halogenoalkyl, halogenoalkenyl, halogenoalkynyl, alkoxy, alkoxycarbonyl, *N*-alkylamino, *N,N*-dialkylamino, a saturated or unsaturated 5- or 6-membered cyclic hydrocarbon group which may have a substituent, a saturated or unsaturated bicyclic or tricyclic condensed hydrocarbon group which may have a substituent, a saturated or unsaturated 5- to 7-membered heterocyclic group which may have a substituent selected from the group

consisting of furyl, thienyl, pyrazolyl, imidazolyl, pyrazolinyl, oxazolyl, isoxazolyl, oxazolinyl, thiazolyl, thiazolinyl, thiadiazolyl, furazanyl, pyranyl, pyridyl, tetrahydropyridyl, pyrimidinyl, pyrazinyl, piperazinyl, pyrrolidinyl, piperidinyl, oxazinyl, oxadiazinyl, morpholinyl, thiazinyl, thiadiazinyl, thiomorpholinyl, tetrazolyl, triazolyl, triazinyl, azepinyl, diazepinyl and triazepinyl;
or a saturated or unsaturated bicyclic or tricyclic condensed heterocyclic group which may have a substituent selected from the group consisting of indolyl, indolinyl, isoindolyl, isoindolinyl, indazolyl, quinolyl, dihydroquinolyl, tetrahydroquinolyl, isoquinolyl, tetrahydroisoquinolyl, 4H-quinolizinyl, quinazolinyl, dihydroquinazolinyl, tetrahydroquinazolinyl, cinnolinyl, tetrahydrocinnolinyl, indolizinyl, tetrahydroindolizinyl, benzothiazolyl, tetrahydrobenzothiazolyl, benzoxazolyl, benzoisothiazolyl, benzoisooxazolyl, benzoimidazolyl, naphthyridinyl, tetrahydronaphthyridinyl, thienopyridyl, tetrahydrothienopyridyl, thiazolopyridyl, tetrahydrothiazolopyridyl, thiazolopyridazinyl, tetrahydrothiazolopyridazinyl, pyrrolopyridyl, dihydropyrrolopyridyl, tetrahydropyrrolopyridyl, pyrrolopyrimidinyl, dihydropyrrolopyrimidinyl, pyridopyrimidinyl, tetrahydropyridopyrimidinyl, pyranothiazolyl, dihydropyranothiazolyl, fuopyridyl, tetrahydrofuopyridyl, oxazolopyridyl, tetrahydrooxazolopyridyl, oxazolopyridazinyl, tetrahydrooxazolopyridazinyl, pyrrolothiazolyl, dihydropyrrolothiazolyl, pyrrolooxazolyl, dihydropyrrolooxazolyl, thienopyrrolyl, thiazolopyrimidinyl, thiazolooxazolyl, imidazothiazolyl, imidazooxazolyl, imidazopyrimidinyl, imidazopyridyl, tetrahydroimidazopyridyl, pyrazinopyridazinyl, imidazotriazinyl, oxazolopyridyl, benzoazepinyl, benzoazepinyl, tetrahydrobenzoazepinyl, benzodiazepinyl, benzotriazepinyl, thienoazepinyl, tetrahydrothienoazepinyl, thienodiazepinyl, thienotriazepinyl, thiazoloazepinyl, and tetrahydrothiazoloazepinyl, wherein the substituent represents one

substituent or 2 or 3 substituents, which are the same or different, selected from the following

Group (C):

Group (C):

halogen, hydroxyl, alkyl, alkoxy, halogenoalkyl, halogenoalkenyl, halogenoalkoxy, cyano, amino, nitro, *N*-alkylamino, *N,N*-dialkylamino, *N*-alkylaminoalkyl, *N,N*-dialkylaminoalkyl, hydroxyalkyl, carboxyl, carboxyalkyl, alkoxycarbonyl, carbamoyl, mercapto, alkylthio, aminosulfonyl, *N*-alkylaminosulfonyl, *N,N*-dialkylaminosulfonyl, oxo, trialkyltin and trialkylsilyl,

or a salt thereof or a solvate thereof.

2-5. (canceled).

6. (currently amended): The compound represented by formula (I) according to claim 1 wherein G is halogen, halogenoalkenyl, alkoxy, alkoxycarbonyl, *N,N*-dialkylamino, a saturated or unsaturated 5- or 6-membered cyclic hydrocarbon group which may have a substituent, or a saturated or unsaturated 5- to 7-membered heterocyclic group which may have a substituent selected from the group consisting of furyl, thienyl, pyrazolyl, imidazolyl, pyrazolinyl, oxazolyl, isoxazolyl, oxazolinyl, thiazolyl, thiazolinyl, thiadiazolyl, furazanyl, pyranyl, pyridyl, tetrahydropyridyl, pyrimidinyl, pyrazinyl, piperazinyl, piperidinyl, oxazinyl, oxadiazinyl, morpholinyl, thiazinyl, thiadiazinyl, thiomorpholinyl, tetrazolyl, triazolyl, triazinyl, azepinyl, diazepinyl and triazepinyl, or a salt thereof or a solvate thereof.

7. (withdrawn-currently amended): The compound represented by formula (I) according to claim 1, wherein any one of R^1 , R^2 , R^3 , Ar and G is labeled with a radiation-releasing isotope, or a salt thereof ~~or a solvate thereof~~.

8. (withdrawn-currently amended): The compound represented by formula (I) according to claim 7, wherein the radiation-releasing isotope is a radioactive iodine atom, or a salt thereof ~~or a solvate thereof~~.

9. (canceled).

10. (currently amended): A pharmaceutical composition which comprises the compound represented by formula (I) according to claim 1, or a salt thereof ~~or a solvate thereof~~, and a pharmaceutically acceptable carrier.

11-13. (canceled).

14. (currently amended): An agent for ~~preventing and/or treating Alzheimer disease, Down syndrome, Creutzfeldt-Jacob disease~~ or, ~~diabetes mellitus type II, dialysis amyloidosis, AA amyloidosis, Gerstmann Straussler Scheinker syndrome, Maxwell's syndrome, localized atrial amyloid, medullary carcinoma of thyroid, skin amyloidosis, localized nodular amyloidosis, AL amyloidosis, AH amyloidosis, familial amyloid polyneuropathy, senile systemic amyloidosis, cerebrovascular amyloidosis, familial Mediterranean fever, Parkinson disease,~~

~~tauopathy, ALS or CAG-repeat disease,~~ which comprises the compound represented by formula (I) according to ~~any one of claims~~claim 1, or a salt thereof ~~or a solvate thereof~~.

15. (withdrawn-currently amended): A radioactive diagnosing agent, which comprises the compound represented by formula (I) according to claim 7, or a salt thereof ~~or a solvate thereof~~.

16-17. (canceled).

18. (withdrawn-currently amended): A method for ~~preventing and/or treating~~ Alzheimer disease, Down syndrome, Creutzfeldt-Jacob disease, ~~diabetes mellitus type II, dialysis amyloidosis, AA amyloidosis, or~~ Gerstmann Straussler Scheinker syndrome, ~~Maxwell's syndrome, localized atrial amyloid, medullary carcinoma of thyroid, skin amyloidosis, localized nodular amyloidosis, AL amyloidosis, AH amyloidosis, familial amyloid polyneuropathy, senile systemic amyloidosis, cerebrovascular amyloidosis, familial Mediterranean fever, Parkinson disease, tauopathy, ALS or CAG-repeat disease,~~ which comprises administering the compound represented by formula (I) according to claim 1, or a salt thereof ~~or a solvate thereof~~.

19. (withdrawn-currently amended): A method for diagnosing accumulation of amyloid, which comprises administering the compound represented by formula (I) according to claim 7, or a salt thereof ~~or a solvate thereof~~, and detecting a radiation-releasing isotope.

Claims 20-23 (canceled).


24. (new): The compound of claim 1 according to formula (I), wherein G represents a saturated or unsaturated 5- to 7- membered heterocyclic group which may have a substituent selected from the group consisting of furyl, thienyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, pyridyl, pyrimidinyl, pyrazinyl and triazinyl.

25. (new): The compound of formula (I) according to claim 1, wherein G represents a saturated or unsaturated bicyclic or tricyclic condensed heterocyclic group which may have a substituent selected from the group consisting of isoindolinyl, quinolyl, tetrahydroquinolyl, isoquinolyl, tetrahydroisoquinolyl, benzothiazolyl, benzoxazolyl, benzoimidazolyl, thienopyridyl, thiazolopyridyl, tetrahydrothiazolopyridyl, pyrrolopyridyl, pyrrolopyrimidinyl, oxazolopyridyl, tetrahydrooxazolopyridyl, imidazothiazolyl, imidazooxazolyl, imidazopyrimidinyl, imidazopyridyl, tetrahydroimidazopyridyl.

26. (new): The compound of formula (I) according to claim 25, wherein G represents a saturated or unsaturated bicyclic or tricyclic condensed heterocyclic group which may have a substituent selected from the group consisting of tetrahydroquinolyl, tetrahydrothiazolopyridyl, imidazothiazolyl, imidazooxazolyl, imidazopyrimidinyl, imidazopyridyl and tetrahydroimidazopyridyl.

27. (new): The compound of formula (I) according to claim 1, wherein G represents a fluorine atom, an iodine atom, 2-fluoroethyl, 3-fluoropropyl, methoxy, oxazolyl, pyridyl, oxadiazolyl, imidazopyridyl, imidazothiazolyl and benzothiazolyl.

28. (new): A method for treating Creutzfeldt-Jacob disease or Gerstmann Straussler Scheinker syndrome, which comprises administering a compound represented by formula (I):



wherein

R¹ represents hydrogen;

R² represents hydrogen, alkyl, amino, cyano, halogen, halogenoalkenyl, carboxyl, alkoxy carbonyl, carbamoyl, *N,N*-dialkylcarbamoyl, *N*-hydroxyalkylcarbamoyl, aryl which may have a substituent, a saturated or unsaturated 5- to 7-membered heterocyclic group which may have a substituent, or a saturated or unsaturated bicyclic or tricyclic condensed heterocyclic group which may have a substituent, wherein the substituent is one substituent or 2 or 3 substituents, which are the same or different, selected from the following Group (A):

Group (A):

halogen, hydroxyl, alkyl, alkoxy, halogenoalkyl, cyano, nitro, hydroxyalkyl, carboxyl, alkoxy carbonyl, carboxyalkoxy, alkoxy carbonylalkoxy, aralkyloxy, *N*-alkylaminoalkylcarbonyl, *N,N*-dialkylaminoalkylcarbonyl, carboxyalkyl, alkoxy carbonylalkoxy, morpholinocarbonylalkoxy, mercapto, alkylthio, aminosulfonyl, *N*-alkylaminosulfonyl, *N,N*-dialkylaminosulfonyl, sulfo, alkylsulfonyl, alkylsulfonylalkyl, tetrazolyl, trialkyltin, trialkylsilyl, aminosulfonylalkyl, *N*-alkylaminosulfonylalkyl, *N,N*-dialkylaminosulfonylalkyl, aralkyl, alkylsulfonylamino, *N*-alkylaminosulfonylamino, *N,N*-dialkylaminosulfonylamino, *N*-alkylaminoacylamino, *N,N*-dialkylaminoacylamino,

a group represented by the following formula (II):



wherein A^1 represents a single bond or linear, branched or cyclic alkylene having from 1 to 6 carbon atoms which may be substituted with halogen or hydroxyl; and Y^1 represents a saturated or unsaturated 5- to 7-membered heterocyclic group which may have a substituent,

wherein the substituent on Y^1 is one substituent or 2 or 3 substituents, which are the same or different, selected from the group consisting of halogen, alkyl, halogenoalkyl, carboxyl, alkoxycarbonyl, aminoalkyl, *N*-alkylamino, *N,N*-dialkylamino, *N*-alkylaminoalkyl, *N,N*-dialkylaminoalkyl, *N*-alkyl-*N*-alkoxycarbonylamino and *N*-alkyl-*N*-alkoxycarbonylaminoalkyl,


a group represented by the following formula (III)



wherein A^2 represents a single bond, linear, branched or cyclic alkylene having from 1 to 6 carbon atoms which may be substituted with halogen or hydroxyl, or linear, branched or cyclic-O-alkylene having from 1 to 6 carbon atoms which may be substituted with halogen or hydroxyl, in which the alkylene binds to the carbonyl in the group; and Y^2 represents a saturated or unsaturated 5- to 7-membered heterocyclic group which may have a substituent,

wherein the substituent on Y^2 represents one substituent or 2 or 3 substituents, which are the same or different, selected from the group consisting of halogen, alkyl, halogenoalkyl, carboxyl, alkoxycarbonyl, aminoalkyl, *N*-alkylamino, *N,N*-dialkylamino, *N*-alkylaminoalkyl, *N,N*-dialkylaminoalkyl, *N*-alkyl-*N*-alkoxycarbonylamino and *N*-alkyl-*N*-alkoxycarbonylaminoalkyl,

a group represented by the following formula (IV)



wherein A³ represents a single bond, linear, branched or cyclic alkylene having from 1 to 6 carbon atoms which may be substituted with halogen or hydroxyl, linear, branched or cyclic-O-alkylene having from 1 to 6 carbon atoms which may be substituted with halogen or hydroxyl, in which the alkylene binds to the nitrogen atom in the group, or linear, branched or cyclic-(C=O)-alkylene having from 1 to 6 carbon atoms which may be substituted with halogen or hydroxyl, in which the alkylene binds to the nitrogen atom in the group; and R⁴ and R⁵ each independently represents hydrogen, alkyl, hydroxyalkyl, halogenoalkyl, acyl, alkoxy carbonyl, alkylsulfonyl, *N*-alkylaminosulfonyl, *N,N*-dialkylaminosulfonyl, *N*-alkylaminoalkylcarbonyl, *N,N*-dialkylaminoalkylcarbonyl or alkyl diphenylsilyloxyalkyl, and

a group represented by the following formula (V)



wherein A⁴ represents a single bond, linear, branched or cyclic alkylene having from 1 to 6 carbon atoms which may be substituted with halogen or hydroxyl, or linear, branched or cyclic-O-alkylene having from 1 to 6 carbon atoms which may be substituted with halogen or hydroxyl, in which the alkylene binds to the carbonyl in the group; and

R⁶ and R⁷ each independently represents hydrogen, alkyl, hydroxyalkyl, halogenoalkyl, acyl, alkoxy carbonyl, alkylsulfonyl, *N*-alkylaminosulfonyl, *N,N*-dialkylaminosulfonyl, *N*-alkylaminoalkylcarbonyl, *N,N*-dialkylaminoalkylcarbonyl or alkyl diphenylsilyloxyalkyl;

R³ represents hydrogen;

Ar represents phenylene, which may have one substituent or 2 or 3 substituents, which are the same or different, selected from the following Group (B):

Group (B):

halogen, hydroxyl group, alkyl, alkoxy, halogenoalkyl, cyano, amino, nitro, alkylamino, hydroxyalkyl, carboxyl, alkoxycarbonyl, carbamoyl, mercapto, alkylthio, aminosulfonyl, *N*-alkylaminosulfonyl, *N,N*-dialkylaminosulfonyl, sulfo, trialkyltin and trialkylsilyl;

X represents a single bond; and

G represents halogen, halogenoalkyl, halogenoalkenyl, halogenoalkynyl, alkoxy, alkoxycarbonyl, *N*-alkylamino, *N,N*-dialkylamino, a saturated or unsaturated 5- or 6-membered cyclic hydrocarbon group which may have a substituent, a saturated or unsaturated bicyclic or tricyclic condensed hydrocarbon group which may have a substituent, a saturated or unsaturated 5- to 7-membered heterocyclic group which may have a substituent, or a saturated or unsaturated bicyclic or tricyclic condensed heterocyclic group which may have a substituent, wherein the substituent represents one substituent or 2 or 3 substituents, which are the same or different, selected from the following Group (C):

Group (C):

halogen, hydroxyl, alkyl, alkoxy, halogenoalkyl, halogenoalkenyl, halogenoalkoxy, cyano, amino, nitro, *N*-alkylamino, *N,N*-dialkylamino, *N*-alkylaminoalkyl, *N,N*-dialkylaminoalkyl, hydroxyalkyl, carboxyl, carboxyalkyl, alkoxycarbonyl, carbamoyl, mercapto, alkylthio, aminosulfonyl, *N*-alkylaminosulfonyl, *N,N*-dialkylaminosulfonyl, oxo, trialkyltin and trialkylsilyl,

or a salt thereof.